• Read more about Pfizer and the European Commission Enter into Manufacturing Reservation Agreement for mRNA-based Vaccines to Help Protect Against Future Pandemics

NEW YORK, June 30, 2023 — Pfizer Inc. (NYSE: PFE) announced today that it has entered into a manufacturing capacity reservation agreement with the European Health and Digital Executive Agency (HaDEA) of the European Commission (EC), which provides the European Union (EU) access to doses of a mRNA-based vaccine should one be developed to protect against a future pandemic-causing disease.

• Read more about Pfizer and BioNTech Submit Applications to U.S. FDA for Omicron XBB.1.5-Adapted Monovalent COVID-19 Vaccine

• The submissions reflect guidance from FDA and other major health authorities to provide COVID-19 vaccines better matched to currently circulating sublineages
• The companies expect to be ready to ship the adapted vaccines immediately following regulatory authorization/approval

NEW YORK and MAINZ, GERMANY, JUNE 23, 2023 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the companies have submitted regulatory applications to the U.S.

• Read more about Pfizer and BioNTech Initiate Application to European Medicines Agency for Omicron XBB.1.5-Adapted Monovalent COVID-19 Vaccine

• The application reflects guidance from EMA and other major health authorities to provide COVID-19 vaccines better matched to currently circulating sublineages
• The companies expect to be ready to ship the adapted vaccines to EU member states immediately following regulatory approval  
• Application in the U.S. expected to follow in the coming days

NEW YORK and MAINZ, GERMANY, JUNE 23, 2023 — Pfizer Inc.

• Read more about Advisory Committee on Immunization Practices Recommends PREVNAR 20® (20-valent Pneumococcal Conjugate Vaccine) in Infants and Children

NEW YORK, N.Y., June 22, 2023 - Pfizer Inc. (NYSE: PFE) announced today that the U.S.

• Read more about Pfizer’s ABRYSVO™ Receives Recommendation for Use in Older Adults from Advisory Committee on Immunization Practices

• ABRYSVO recommended for adults 60 years and older to help protect against Respiratory Syncytial Virus (RSV) disease 
• Pfizer presented initial data from mid- RSV season two in the Northern Hemisphere, which demonstrated ABRYSVO maintained efficacy against RSV-associated lower respiratory tract disease (LRTD)
• Additional data presented by Pfizer supports coadministration of ABRYSVO with flu vaccine in older adults 

NEW YORK, June 22, 2023 – Pfizer Inc. (NYSE: PFE) announced today that the U.S.

• Read more about 2023 Pride Journal—Stronger Together

• Read more about Pfizer’s Plans to Celebrate Juneteenth 2023

• Read more about ASCO 2023: Partnering with Patients to Bring an End to Cancer

• Read more about Lady Gaga Partners with Pfizer to Raise Migraine Awareness  

• Read more about How to Talk to Children About COVID-19: Reassuring Children During the Coronavirus Pandemic

News of the novel coronavirus COVID-19 seems to be everywhere. Understandably, there is a lot of uncertainty and anxiety about the pandemic. It can be overwhelming and frightening not just for adults but for children as well. But there are steps parents and caregivers can take to help children cope with stress during the outbreak.